198 related articles for article (PubMed ID: 21438721)
1. Anticancer double lipid prodrugs: liposomal preparation and characterization.
Arouri A; Mouritsen OG
J Liposome Res; 2011 Dec; 21(4):296-305. PubMed ID: 21438721
[TBL] [Abstract][Full Text] [Related]
2. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
Arouri A; Mouritsen OG
Eur J Pharm Sci; 2012 Mar; 45(4):408-20. PubMed ID: 21946258
[TBL] [Abstract][Full Text] [Related]
3. Liposomal formulation of retinoids designed for enzyme triggered release.
Pedersen PJ; Adolph SK; Subramanian AK; Arouri A; Andresen TL; Mouritsen OG; Madsen R; Madsen MW; Peters GH; Clausen MH
J Med Chem; 2010 May; 53(9):3782-92. PubMed ID: 20405849
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs.
Andresen TL; Davidsen J; Begtrup M; Mouritsen OG; Jørgensen K
J Med Chem; 2004 Mar; 47(7):1694-703. PubMed ID: 15027860
[TBL] [Abstract][Full Text] [Related]
5. Arsonoliposomes: preparation and physicochemical characterization.
Antimisiaris SG; Ioannou PV
Methods Mol Biol; 2010; 605():147-62. PubMed ID: 20072879
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid.
Linderoth L; Fristrup P; Hansen M; Melander F; Madsen R; Andresen TL; Peters GH
J Am Chem Soc; 2009 Sep; 131(34):12193-200. PubMed ID: 19663381
[TBL] [Abstract][Full Text] [Related]
7. Drug delivery by an enzyme-mediated cyclization of a lipid prodrug with unique bilayer-formation properties.
Linderoth L; Peters GH; Madsen R; Andresen TL
Angew Chem Int Ed Engl; 2009; 48(10):1823-6. PubMed ID: 19173369
[TBL] [Abstract][Full Text] [Related]
8. Lipids, curvature stress, and the action of lipid prodrugs: free fatty acids and lysolipid enhancement of drug transport across liposomal membranes.
Jespersen H; Andersen JH; Ditzel HJ; Mouritsen OG
Biochimie; 2012 Jan; 94(1):2-10. PubMed ID: 21839138
[TBL] [Abstract][Full Text] [Related]
9. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
10. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
Jensen SS; Andresen TL; Davidsen J; Høyrup P; Shnyder SD; Bibby MC; Gill JH; Jørgensen K
Mol Cancer Ther; 2004 Nov; 3(11):1451-8. PubMed ID: 15542784
[TBL] [Abstract][Full Text] [Related]
11. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs.
Pedersen PJ; Christensen MS; Ruysschaert T; Linderoth L; Andresen TL; Melander F; Mouritsen OG; Madsen R; Clausen MH
J Med Chem; 2009 May; 52(10):3408-15. PubMed ID: 19402667
[TBL] [Abstract][Full Text] [Related]
13. Intracellular and serum stability of liposomal 2',3'-dideoxycytidine. Effect of lipid composition.
Makabi-Panzu B; Gourde P; Désormeaux A; Bergeron MG
Cell Mol Biol (Noisy-le-grand); 1998 Mar; 44(2):277-84. PubMed ID: 9593578
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
Bhatia A; Kumar R; Katare OP
J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
[TBL] [Abstract][Full Text] [Related]
15. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
16. Potential dopamine prodrug-loaded liposomes: preparation, characterization, and in vitro stability studies.
Carafa M; Marianecci C; Di Marzio L; De Caro V; Giandalia G; Giannola LI; Santucci E
J Liposome Res; 2010 Sep; 20(3):250-7. PubMed ID: 19958070
[TBL] [Abstract][Full Text] [Related]
17. Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane.
Zhao L; Feng SS
J Colloid Interface Sci; 2005 May; 285(1):326-35. PubMed ID: 15797430
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
Waterhouse DN; Madden TD; Cullis PR; Bally MB; Mayer LD; Webb MS
Methods Enzymol; 2005; 391():40-57. PubMed ID: 15721373
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting microencapsulation of drugs in liposomes.
Kulkarni SB; Betageri GV; Singh M
J Microencapsul; 1995; 12(3):229-46. PubMed ID: 7650588
[TBL] [Abstract][Full Text] [Related]
20. A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary.
Skanji R; Andrieux K; Lalanne M; Caron J; Bourgaux C; Degrouard J; Brisset F; Gueutin C; Chacun H; Dereuddre-Bosquet N; Paci A; Vassal G; Bauduin L; Garcia-Argote S; Rousseau B; Clayette P; Desmaële D; Couvreur P
Int J Pharm; 2011 Jul; 414(1-2):285-97. PubMed ID: 21596125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
